Bonesupport Listed on NASDAQ Stockholm
Last week Swedish orthobiologics company Bonesupport AB was listed on NASDAQ Stockholm. Bonesupport (BONEX) is part of an IPO hot streak on the Nordic markets – it was the 63rd company to be listed in 2017, and one of five companies (Sedana Medical among them) to be listed on the NASDAQ Stockholm on June 21. Five companies to go public on the same day is a record for the listing.
Bonesupport will use proceeds from the offering to fund the company’s growth strategy, including sales and marketing efforts in the U.S. and Europe, collection of clinical data, the Fortify IDE study and investment in their product pipeline. The FORTIFY trial, which enrolled its first patient last month, will support a PMA application in the U.S. for CERAMENT G, an injectable antibiotic-eluting bone graft substitute. The company is pursuing approval for CERAMENT G in open tibial fractures, which are associated with infection and fracture non-union as well as long-term disability.
The first formulation of CERAMENT was 510(k)-cleared in 2008 as a synthetic bone void filler comprised of hydroxyapatite and calcium sulfate. Indications for use include gaps and voids in bone, such as those occurring from trauma and benign bone tumors. The antibiotic-eluting versions of the material, CERAMENT G (gentamicin) and CERAMENT V (vancomycin), have been CE-marked and are available for sale in Europe.
Posted June 26, 2017